Close Menu

IPO

NEW YORK (GenomeWeb News) – Biocept today went public as shares of its common stock began trading at $10, the low end of an anticipated price range on its initial public offering.

Dicerna Pharmaceuticals this week priced its initial public offering of 6 million shares of its common stock at $15 a share — higher than the $13 to $15 range it had previously projected.

Just months after securing the rights to its core intellectual property, microRNA shop Microlin Bio has filed with US regulators for a $25 million initial public offering.

In breaking out its pipeline in detail for the first time as it looks to go public, Dicerna Pharmaceuticals revealed that it is following along with others in the RNAi therapeutics field, namely Alny

Should Dicerna Pharmaceuticals complete its planned initial public offering, the company would be the first RNAi drug developer to go public since Alnylam Pharmaceuticals did so in 2004.

Dicerna Files for $69M IPO

Premium

Dicerna Pharmaceuticals disclosed in a regulatory filing this week that it is planning to raise up to $69 million through an initial public offering of its stock on the Nasdaq.

NEW YORK (GenomeWeb News) – Evogene today announced the closing of its US initial public offering, raising $84.8 million in gross proceeds.

NEW YORK (GenomeWeb News) – Plant genomics firm Evogene has gone public in the US through the offering of 5 million shares of common stock at an offering price of $14.75 per share, bringing in gross proceeds of $73.75 million.

NEW YORK (GenomeWeb News) – Israeli plant genomics company Evogene said in an amended registration statement filed with the US Securities and Exchange Commission on Wednesday that it aims to raise $79 million in net proceeds through its initial public offering in the US.

NEW YORK (GenomeWeb News) – Biocept today set the price range on its planned initial public offering, saying it expects to price its shares between $10 and $12.

Pages

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.